Hansa Medical appoints Medical Advisory Board

Hansa Medical is pleased to announce Professor Kathryn Wood, Professor Christophe Legendre and Professor Gunnar Tufveson as members of Hansa Medical’s Medical Advisory Board. In this capacity, these distinguished experts will bring invaluable medical expertise on kidney transplantation and desensitization to Hansa Medical.

Kathryn Wood is Professor of Immunology in the Nuffield Department of Surgical Sciences, University of Oxford where she runs the Transplantation Research Immunology Group. Professor Wood is an internationally renowned medical researcher in transplant tolerance induction, immune regulation and interaction between the immune system and stem cell derived tissues. She is a Fellow of The Academy of Medical Sciences and has received several international awards for her distinguished research, including the Royal Society Wolfson Merit Award for research excellence. Professor Wood has served as President of the Transplantation Society and currently leads the Women in Transplantation Initiative and functions as editor of the journal Transplantation.

Christophe Legendre is Professor of Nephrology at the Paris Descartes University and Head of the Adult Nephrology and Transplantation unit at Necker Hospital in Paris. Professor Legendre’s main research interests include clinical evaluation of new immunosuppressants, viral infection after transplantation, transplantation in high-risk recipients, screening kidney biopsies and recurrence of disease post transplantation. He has published around 340 papers in English peer reviewed journals. Professor Legendre is member of several professional societies including the American Society of Transplantation, the European Society for Organ Transplantation and the Transplantation Society as well as associate editor of the American Journal of Transplantation and Europe Regional Associate Editor of the journal Transplantation.

Gunnar Tufveson is Professor of Transplant Surgery at Uppsala University and Chief Physician at the Department of Surgical Sciences, at Uppsala University Hospital. Professor Tufveson has more that 30 years of experience in all aspects of kidney and pancreas transplantation. His research has focused on immunological and pathophysiological mechanisms in transplantation, resulting in more than 300 articles and book chapters. Professor Tufveson has served as Primary Investigator in several clinical trials sponsored by the pharmaceutical industry as well as the US National Institutes of Health.

”We feel deeply honored sharing our visions regarding IdeS with these highly acclaimed experts in transplantation. A Medical Advisory Board of such dignity will provide us with invaluable support in the clinical trials of our lead candidate IdeS and in our endeavours trying to enable kidney transplantation for sensitised patients.” comments Emanuel Björne, CEO of Hansa Medical AB (publ).

For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO Hansa Medical AB (publ)
Mobile: 46 707 17 54 77
E-mail: emanuel.bjorne@hansamedical.com
www.hansamedical.com

Hansa Medical pursues clinical development and commercialization of innovative pharmaceuticals and diagnostic methods for the benefit of patients with serious and rare inflammatory diseases. The portfolio includes a marketed diagnostic product, a drug candidate in clinical development, and a preclinical research project. Major shareholders are Bo Håkansson via Farstorps Gård AB, and Nexttobe AB. Hansa Medical is listed on NASDAQ OMX First North (HMED) and Remium Nordic AB is the company’s Certified Adviser. The information in this press release is such information that Hansa Medical AB (publ) is obliged to disclose under the Securities Market Act and/or the Financial Instruments Trading Act. The information was made public on April 10, 2014 at 08:00 CET.

Tags:

About Us

Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (HMED) is listed on Nasdaq First North in Stockholm with Remium Nordic AB as Certified Adviser.

Subscribe

Media

Media

Documents & Links

Quotes

We feel deeply honored sharing our visions regarding IdeS with these highly acclaimed experts in transplantation. A Medical Advisory Board of such dignity will provide us with invaluable support in the clinical trials of our lead candidate IdeS and in our endeavours trying to enable kidney transplantation for sensitised patients
Emanuel Björne, CEO of Hansa Medical AB (publ)